Skip to content

Digital Phenotyping for Changes in Activity at the End of Life in People With Dementia

Digital Phenotyping for Changes in Activity at the End of Life in People With Dementia: an Observational Trial Based on Sensing Technology

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06032091
Acronym
DIPHDEM
Enrollment
50
Registered
2023-09-11
Start date
2023-05-02
Completion date
2026-05-01
Last updated
2024-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dementia

Keywords

end-of-life care

Brief summary

Background: Almost 90% of people with dementia develop serious symptoms such as apathy, agitation, pain, and sleep disturbances. Movement and participation in daily activities also decrease dramatically over time. Traditional measures for these symptoms are usually in the form of a questionnaire and are not very accurate. Technology, such as a smartwatch, can be an effective tool for complementing traditional measures. Currently, there are few studies which look at activity and symptom measurements at the end-of-life. This makes results from this study extremely valuable for future care decisions, especially for people which may not be able to communicate their needs during the end-of-life period. Method/Design: DIgital PHenotyping in DEMentia (DIPH.DEM), a 3-year cross-sectional observational study (N=50), will look at activities, apathy, agitation, and sleep disturbances using sensing technologies to monitor participants at the end of life. The objective of the study is to use a smartwatch and wireless radar (bedside) device (Somnofy), in addition to validated assessment tools to describe the activity patterns for patients with dementia at the end of life (baseline and every 6.months). We hypothesize that this will enable better estimation of time of death, facilitating discussion surrounding improvement of end-of-life interventions and directives. Discussion: The use of sensors (smartwatch and wireless beside device) can provide valuable knowledge on living and dying with dementia, improve end-of-life directives, and provide guidance for timely, appropriate interventions, including referral to palliative services. Impact on society: DIPH.DEM has the potential to enable more timely, precise, and quality care for people with dementia living at home, in nursing homes, and hospitals.

Detailed description

About 90% of people with dementia develop behavioral and psychological symptoms such as agitation, depression and psychosis. In addition, their activity levels decrease over time. Traditional outcome measures can capture physical, mental and social activities of clinical conditions, but usually have low validity. The use of sensor technology in people with dementia is currently poorly validated. DIPH.DEM will examine whether digital tools such as a smartwatch and Somnofy (radar installation) can provide objective measurements of the patient's activities and symptoms throughout the nursing home/hospital stay, including the end of life phase. The participants are people with dementia, \>64 years, who are living in a nursing home. A selection of traditional tools and sensor data is collected at baseline and every 6 months (7 days continuous monitoring). If the participant has a significant change in health status, we will begin with continuous sensor measurements until the end of life (up to 12 weeks). DIPH.DEM can provide valuable information on activity development and symptom presentation toward the end of life in people with dementia. Informal caregivers (usually a family member) will be included to assist with the outcome measures within the study. Participants will be recruited from the Health Region West Norway and Bergen Municipality (sampling method is by invitation to volunteer). All consent procedures will be developed in accordance with Norwegian law.

Interventions

OTHERNo intervention

The study is observational and will not include any specific interventions other than the regular care practice that the participants receive from their care providers. The study will use a wrist-mounted smartwatch for monitoring. Previous studies show acceptability toward wearable devices among persons with dementia; however, if the care staff recognize discomfort or distress caused by the device, it will be immediately removed.

Sponsors

Helse Vest
CollaboratorOTHER
Haukeland University Hospital
CollaboratorOTHER
Haraldsplass Deaconess Hospital
CollaboratorOTHER
Bergen Red Cross Nursing Home
CollaboratorUNKNOWN
University of Bergen
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* People with dementia or who have a likely diagnosis of dementia * Hospital (admitted for \>3 days) * Nursing home resident * \>64 years old * Score of \<4 on the 4 A's Test for Delirium (4AT) will be required for inclusion (no delirium)

Exclusion criteria

* People without dementia or cognitive impairment * People that are considered already in a health status emergency (\< 6 weeks to live) * People that are not living in the nursing home

Design outcomes

Primary

MeasureTime frameDescription
Activities of Daily Living (ADL) - Physical Self Maintenance Scale (PSMS), Lawton and Brody, 1969.Baseline and every 6.months (up to one year)Personal functional daily activities such as toileting, eating, self-care, movement/ambulation, transfers, bathing. 6 sections - scoring 1-5 on each, higher score indicates greater disability.
Digital biomarker estimations for apathy, agitation, pain, and sleep disturbancesBaseline and every 6.months (up to one year), continuous up to 12 weeks if a serious health event occursEstimation of activity changes and selected behavioral disturbances resulting from the combined digital phenotype modeling; these estimations are experimental and scores will be based on analysis of found data after data collection period.

Secondary

MeasureTime frameDescription
Mobilization, Observation, Behavioral, Intensity Dementia (MOBID-2)Baseline and every 6.months (up to one year)Measurement of pain specific to a dementia population; visual analog scale alongside likert scale 0-10, 0 being no pain and 10 being the worst pain, validated with persons with dementia
Neuropsychiatric Inventory - Nursing Home Version (NPI-NH)Baseline and every 6.months (up to one year)Validated in Norwegian nursing homes, measuring symptoms of behavioral and psychological symptoms of dementia (BPSD) such as: apathy, agitation, depression, anxiety, sleep disturbance, and appetite/eating. Gives scores 1-4 (higher numbers being daily occurance) for amount, 1-3 for intensity and burden of care related to symptom for caregiver (1-5) for each symptom.
InterRai-Palliative Care (InterRai-PC)Baseline and every 6.months (up to one year)Oral health section only/specific of the InterRai-PC, assessment of symptoms
Digital secondary outcomesBaseline and every 6.months (up to one year)Device-native scores for activity and sleep.
Edmonton Symptom Assessment System (ESAS++)Baseline and every 6.months (up to one year)Symptom assessment for palliative care period and the end of life period, with added items: death rattle, dyspnea, sleep disturbances, emesis specific to end of life. Likert scale 0-10; 0 indicating no symptoms and 10 is worst symptom.

Other

MeasureTime frameDescription
Clinical Dementia Rating (CDR)BaselineClassification of cognitive impairment, 0 no cognitive impairment, 0.5 questionable impairment, 1 mild cognitive impairment, 2 moderate cognitive impairment, 3 severe cognitive impairment.
4 A's Test for Delirium (4AT)BaselineDistinction between dementia and delirium for inclusion to study, \>4 indicates delirium; will be used as an exclusion criteria (particpants must score \<4)
Clinical Frailty Scale (CFS)BaselineMortality risk measure for general wellbeing, higher scores indicate greater disability (1-9)
General Medical Health Rating Scale (GMHR)BaselineMortality risk measure for general wellbeing, medical comorbidity, degree of somatic illness; top 2 scores are good, bottom 2 indicate serious illness with comorbidities. Bedside measure validated in NH with people with dementia.
Chart reviewBaselineA medication list will be compiled according to the Anatomical Therapeutic Chemical classification (ATC codes) and the Defined Daily Dose (DDD) of regularly scheduled treatments.

Countries

Norway

Contacts

Primary ContactLydia Dawn Boyle, MSc, DPT
lydia.boyle@uib.no+4740518081
Backup ContactMonica Patrascu, Eng, PhD
monica.patrascu@uib.no+4755588501

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026